With a robust background in technology and healthcare investments, the fund manager has successfully completed over 30 deals, demonstrating a strong focus on early-stage opportunities. Active primarily in North America and Europe, they emphasize a data-driven approach to identify transformative companies. Their portfolio features notable exits, including several in the biotech sector, underscoring their expertise in navigating complex markets. This operator-first strategy allows for deep engagement with founders, fostering innovation and growth within their investments.